Ad is loading...
CRVO
Price
$9.58
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
FATE
Price
$2.07
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
101 days until earnings call
Ad is loading...

CRVO vs FATE

Header iconCRVO vs FATE Comparison
Open Charts CRVO vs FATEBanner chart's image
CervoMed
Price$9.58
Change-$0.00 (-0.00%)
Volume$62.61K
CapitalizationN/A
Fate Therapeutics
Price$2.07
Change-$0.00 (-0.00%)
Volume$2.01M
CapitalizationN/A
CRVO vs FATE Comparison Chart
Loading...
CRVO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CRVO vs. FATE commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVO is a Hold and FATE is a Hold.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (CRVO: $9.58 vs. FATE: $2.07)
Brand notoriety: CRVO and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVO: 76% vs. FATE: 105%
Market capitalization -- CRVO: $79.07M vs. FATE: $260.82M
CRVO [@Biotechnology] is valued at $79.07M. FATE’s [@Biotechnology] market capitalization is $260.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVO’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • CRVO’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, both CRVO and FATE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVO’s TA Score shows that 4 TA indicator(s) are bullish while FATE’s TA Score has 4 bullish TA indicator(s).

  • CRVO’s TA Score: 4 bullish, 4 bearish.
  • FATE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CRVO and FATE are a good buy in the short-term.

Price Growth

CRVO (@Biotechnology) experienced а -12.27% price change this week, while FATE (@Biotechnology) price change was -0.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +4.04%.

Reported Earning Dates

CRVO is expected to report earnings on Nov 13, 2023.

FATE is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($261M) has a higher market cap than CRVO($79.2M). CRVO YTD gains are higher at: 25.557 vs. FATE (-44.652). CRVO has higher annual earnings (EBITDA): -7.83M vs. FATE (-177.57M). FATE has more cash in the bank: 297M vs. CRVO (46.7M). CRVO has less debt than FATE: CRVO (0) vs FATE (99M). FATE has higher revenues than CRVO: FATE (13.4M) vs CRVO (0).
CRVOFATECRVO / FATE
Capitalization79.2M261M30%
EBITDA-7.83M-177.57M4%
Gain YTD25.557-44.652-57%
P/E Ratio4.73N/A-
Revenue013.4M-
Total Cash46.7M297M16%
Total Debt099M-
FUNDAMENTALS RATINGS
CRVO vs FATE: Fundamental Ratings
CRVO
FATE
OUTLOOK RATING
1..100
5676
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
19
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
9090
P/E GROWTH RATING
1..100
75100
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (19) in the Biotechnology industry is in the same range as CRVO (42). This means that FATE’s stock grew similarly to CRVO’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRVO (100). This means that FATE’s stock grew similarly to CRVO’s over the last 12 months.

FATE's SMR Rating (97) in the Biotechnology industry is in the same range as CRVO (97). This means that FATE’s stock grew similarly to CRVO’s over the last 12 months.

FATE's Price Growth Rating (90) in the Biotechnology industry is in the same range as CRVO (90). This means that FATE’s stock grew similarly to CRVO’s over the last 12 months.

CRVO's P/E Growth Rating (75) in the Biotechnology industry is in the same range as FATE (100). This means that CRVO’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVOFATE
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 24 days ago
80%
Bullish Trend 19 days ago
86%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CRVO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SWIM6.320.45
+7.67%
Latham Group
AXTA39.780.89
+2.29%
Axalta Coating Systems Ltd
EPIX1.760.03
+1.73%
ESSA Pharma
MSGE36.220.57
+1.60%
Madison Square Garden Entertainment Corp
CVX161.630.30
+0.19%
Chevron Corp

CRVO and

Correlation & Price change

A.I.dvisor tells us that CRVO and VIRX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CRVO and VIRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVO
1D Price
Change %
CRVO100%
-0.62%
VIRX - CRVO
28%
Poorly correlated
N/A
VKTX - CRVO
27%
Poorly correlated
+0.19%
NKTR - CRVO
27%
Poorly correlated
+1.00%
AVXL - CRVO
27%
Poorly correlated
+6.43%
FATE - CRVO
25%
Poorly correlated
-6.76%
More